(Q35259954)

7 August 2017

1 reference

title

New therapies for ovarian cancer (English)

1 reference

7 August 2017

1 reference

R. J. Schilder

1

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?resulttype=core&format=json&query=SRC%3AMED%20AND%20EXT_ID%3A1352730

17 September 2022

R. F. Ozols

series ordinal

2

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?resulttype=core&format=json&query=SRC%3AMED%20AND%20EXT_ID%3A1352730

17 September 2022

language of work or name

English

1 reference

National Center for Biotechnology Information

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/esummary.fcgi?db=pubmed&retmode=json&id=1352730

17 September 2022

publication date

1 January 1992

1 reference

7 August 2017

1 reference

7 August 2017

10

1 reference

7 August 2017

307-315

1 reference

7 August 2017

4

1 reference

Adjuvant therapy in stage I and stage II epithelial ovarian cancer. Results of two prospective randomized trials

7 August 2017

1 reference

https://api.crossref.org/works/10.3109%2F07357909209032755

Resistance to alkylating agents and cisplatin: insights from ovarian carcinoma model systems

21 January 2018

1 reference

https://api.crossref.org/works/10.3109%2F07357909209032755

Multiple-drug resistance in human cancer

21 January 2018

1 reference

https://api.crossref.org/works/10.3109%2F07357909209032755

A randomized study of cyclophosphamide and cis-platinum with or without doxorubicin in advanced ovarian carcinoma

21 January 2018

1 reference

https://api.crossref.org/works/10.3109%2F07357909209032755

Overexpression of metallothionein confers resistance to anticancer drugs.

21 January 2018

1 reference

https://api.crossref.org/works/10.3109%2F07357909209032755

Metallothionein gene expression and resistance to cisplatin in human ovarian cancer

21 January 2018

1 reference

https://api.crossref.org/works/10.3109%2F07357909209032755

Augmentation of adriamycin, melphalan, and cisplatin cytotoxicity in drug-resistant and -sensitive human ovarian carcinoma cell lines by buthionine sulfoximine mediated glutathione depletion.

21 January 2018

1 reference

https://api.crossref.org/works/10.3109%2F07357909209032755

Enhanced DNA repair as a mechanism of resistance to cis-diamminedichloroplatinum(II).

21 January 2018

1 reference

https://api.crossref.org/works/10.3109%2F07357909209032755

Cyclophosphamide-cisplatin versus cyclophosphamide-carboplatin in stage III-IV ovarian carcinoma: a comparison of equally myelosuppressive regimens

21 January 2018

1 reference

https://api.crossref.org/works/10.3109%2F07357909209032755

Cisplatin/carboplatin cross-resistance in ovarian cancer

21 January 2018

1 reference

https://api.crossref.org/works/10.3109%2F07357909209032755

Biological properties of ten human ovarian carcinoma cell lines: calibration in vitro against four platinum complexes

21 January 2018

1 reference

https://api.crossref.org/works/10.3109%2F07357909209032755

Taxol: a novel investigational antimicrotubule agent

21 January 2018

1 reference

https://api.crossref.org/works/10.3109%2F07357909209032755

High-dose cisplatin in hypertonic saline in refractory ovarian cancer

21 January 2018

1 reference

https://api.crossref.org/works/10.3109%2F07357909209032755

High-dose cisplatin with sodium thiosulfate protection.

21 January 2018

1 reference

https://api.crossref.org/works/10.3109%2F07357909209032755

High-dose carboplatin in refractory ovarian cancer patients.

21 January 2018

1 reference

https://api.crossref.org/works/10.3109%2F07357909209032755

Cisplatin combined with carboplatin: a new way of intensification of platinum dose in the treatment of advanced ovarian cancer. Belgian Study Group for Ovarian Carcinoma

21 January 2018

1 reference

https://api.crossref.org/works/10.3109%2F07357909209032755

Efficacy of Ondansetron (Gr 38032F) and the Role of Serotonin in Cisplatin-Induced Nausea and Vomiting

21 January 2018

1 reference

https://api.crossref.org/works/10.3109%2F07357909209032755

Comparison of the 5-hydroxytryptamine3 (serotonin) antagonist ondansetron (GR 38032F) with high-dose metoclopramide in the control of cisplatin-induced emesis.

21 January 2018

1 reference

https://api.crossref.org/works/10.3109%2F07357909209032755

Prevention of cisplatin neurotoxicity with an ACTH(4-9) analogue in patients with ovarian cancer

21 January 2018

1 reference

https://api.crossref.org/works/10.3109%2F07357909209032755

Cisplatin neuropathy. Risk factors, prognosis, and protection by WR-2721.

21 January 2018

1 reference

https://api.crossref.org/works/10.3109%2F07357909209032755

Long-term survival of advanced refractory ovarian carcinoma patients with small-volume disease treated with intraperitoneal chemotherapy

21 January 2018

1 reference

https://api.crossref.org/works/10.3109%2F07357909209032755

Intraperitoneal cisplatin and etoposide in the treatment of refractory/recurrent ovarian carcinoma

21 January 2018

1 reference

https://api.crossref.org/works/10.3109%2F07357909209032755

Carboplatin/etoposide as first-line chemotherapy in advanced ovarian carcinoma: a pilot study

21 January 2018

1 reference

https://api.crossref.org/works/10.3109%2F07357909209032755

Intraperitoneal recombinant alpha-2-interferon alternating with cisplatin as salvage therapy for minimal residual-disease ovarian cancer: a phase II study

21 January 2018

1 reference

https://api.crossref.org/works/10.3109%2F07357909209032755

Aphidicolin prevents mitotic cell division by interfering with the activity of DNA polymerase-alpha

21 January 2018

1 reference

https://api.crossref.org/works/10.3109%2F07357909209032755

10.3109/07357909209032755

21 January 2018

Identifiers

DOI

1 reference

7 August 2017

1 reference